Diabetes is one of the most prevalent comorbidities among patients with COVID-19, and specific minorities in the United States are being disproportionately affected. The biologic mechanism underpinning this association is still unknown; however, there are known causal relationships between hyperglycemia and dysregulated immunity in the diabetic population in sepsis and acute respiratory distress syndrome. Diabetes may impact the pathogenicity of SARS-CoV-2, possibly via glycosylation of a key receptor, ACE2. It is imperative that we further understand this link in order to attenuate the critical illness caused by COVID-19 among diabetics.
Diabetes, COVID-19, ACE2
Access all of the content
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!